However, increased PD-1, PD-L1, and PD-L2 expression were found more on breast cancer patients with higher ages (>40 years), ductal histology, higher grade, positive estrogen receptor (ER) status, negative HER2 status, and positive progesterone receptor (PR) status (Table 2). This evidence concerns the gene ERBB2 and breast carcinoma.